Navigation Links
Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce First Patient Dosed in Phase II Study of VPD-737 in Prurigo Nodularis
Date:8/4/2014

SOUTH SAN FRANCISCO, Calif., Aug. 4, 2014 /PRNewswire/ -- Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") today announced that the first patient has been dosed in a double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of VPD-737 (serlopitant), administered orally in patients with prurigo nodularis.  Separately, VPD is also conducting a Phase II clinical trial in the United States evaluating VPD-737 in patients with chronic pruritus.

Dr. Edward Schnipper, Tigercat's Chief Medical Officer, stated "We are delighted to announce that the first patient has been dosed in this important Phase II study.  Prurigo nodularis is a debilitating disease and the current standard of care does not effectively address this condition.  We believe VPD-737 is a promising pharmacological option and we are eager to see results from this study, which along with data from our chronic pruritus study, will be available in 2015."

The trial is a double-blind, placebo-controlled Phase II study in sixty patients with prurigo nodularis, an orphan disease.  The study is designed to determine the safety, tolerability, and efficacy of VPD-737, an NK-1 receptor antagonist, and is underway at four sites in Germany.  Patients in the study will receive either 5 mg of VPD-737 or placebo, taken once daily, for a period of eight weeks.

VPD-737 was exclusively licensed by Merck to VPD in 2012.

About Tigercat Pharma, Inc.
Tigercat Pharma, Inc., is a largely "virtual" company which was created to hold the ownership of the VPD-737 development program.  Tigercat is funded by Velocity Pharmaceutical Holdings, LLC, and Remeditex Ventures, LLC.  The VPD-737 development program is managed under contract by VPD. 

About Velocity Pharmaceutical Development, LLC 
VPD is a
'/>"/>

SOURCE Velocity Pharmaceutical Development, LLC
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Velocity Pharmaceutical Development Announces Appointment of Stuart Sedlack as Senior Vice President, Business Development
2. Velocity Pharmaceutical Development and Remeditex Ventures Announce Collaboration Agreement and Initial Co-Investment
3. Pharmaceuticals Learning the Language of the New Healthcare Landscape
4. Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
5. Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
6. Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014
7. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
8. Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014
9. Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs
10. The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
11. Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BOSTON , September 16, 2014 ... Fiona Marshall , will give a presentation entitled " ... StaR ®   technology " ... and Development " virtual symposium run by Chemical & Engineering ... symposium is on Wednesday, 24 September 2014; Dr Marshall,s presentation ...
(Date:9/15/2014)... FRANCISCO , Sept. 15, 2014 ... studies presented at the American Society for Radiation ... its Decipher® Prostate Cancer Classifier, a genomic test ... influence treatment decisions and improve patient outcomes for ... These presentations follow a recently published study that ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data on the ... report provides value, in millions of US dollars, ... dollars) within market segments Invasive Body Contouring Devices ... Radio Frequency-Assisted Liposuction (RFAL) Devices, Ultrasound-Assisted Liposuction (UAL) ...
Breaking Medicine Technology:Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 2Two New Studies Show Decipher Genomic Prostate Cancer Test Charts Best Course of Treatment and Influences Patient Outcomes 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 4Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 5
... 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems ... emerging leader in the development, assembly, marketing and sale ... today announced that it was granted three new patents ... of China ("SIPO"). The patent awards were related to ...
... Cellular Dynamics International (CDI) today announced the online publication ... demonstrating for the first time a methodology for researchers ... blood samples through the creation of induced pluripotent stem ... B-cell lines reprogrammed to EBV-free induced pluripotent stem cells," ...
Cached Medicine Technology:Dehaier Strengthens Intellectual Property Portfolio 2Dehaier Strengthens Intellectual Property Portfolio 3Cellular Dynamics International Unlocks the Potential of Banked Blood Samples 2
(Date:9/16/2014)... Discussion abstracts to be presented at the ESMO 2014 ... 2014 at 12:00 (CEST) to give you a first ... medical oncology Congress, under the leading theme Precision Medicine ... where genuinely targeted therapy is now possible for an ... are all working towards a common goal --improved patient ...
(Date:9/16/2014)... Perkins, OK (PRWEB) September 16, 2014 ... Superfood, rich in iron and potassium. They are ... high nutritional values and their healing and health ... and meaty texture Shiitakes can stimulate and strengthen ... infections. Shiitakes contain polycharrides, including beta ...
(Date:9/16/2014)... Atlanta, GA (PRWEB) September 16, 2014 ... cloud-based clinical, business management and billing software solutions ... immediate availability of its latest release of ... providers, orthotics and prosthetics providers as well as ... for prior authorization requests (PARs), electronic purchasing, document ...
(Date:9/16/2014)... Albany, New York (PRWEB) September 16, 2014 ... intelligence firm states that the global facial care market ... billion by 2019. The report, titled ‘Facial Care Market ... Facial Creams, Face Wash, Cleansing Wipes, Serums and Masks ... Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 ...
(Date:9/16/2014)... Cloud based mobile app builder Appy ... API’S to serve m3u8 streams on Android & iOS. ... video events with hundreds of thousands of simultaneous viewers ... is known for making beautiful and interactive apps for ... 8 and already over 100,000 apps have passed through ...
Breaking Medicine News(10 mins):Health News:ESMO 2014 Congress Preview 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3Health News:Brightree Announces Availability of Latest Release 2Health News:Brightree Announces Availability of Latest Release 3Health News:Brightree Announces Availability of Latest Release 4Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
... their seatbelts than the rest of the population, adding ... growing problem. , The connection was made by ... Meharry Medical College in Nashville, Tenn. , We found ... Schlundt, associate professor of psychology and assistant professor of ...
... as a non-invasive way to determine the existence and ... development of pharmacologic strategies to combat the condition. These ... journal published by John Wiley & Sons on behalf ... Diseases (AASLD). The article is also available online at ...
... two editorials published in the September 2007 issue ... medical ethicist discussed whether doctors should participate in ... discussions about physician involvement in capital punishment have ... court systems. And the North Carolina Medical Board ...
... Commissioner Dr. Thomas R. Frieden, and Consumer Affairs Commissioner Jonathan ... City Youth Risk Behavior Survey (YRBS) showing that cigarette smoking ... 2005 and 2007. The citys teen smoking rate has dropped ... 17.6 percent in 2001 to 8.5 percent in 2007. The ...
... BOSTON, Mass. (Jan. 2, 2008) Athanasios Zavras began ... reports linked oral osteoporosis meds to bone death in ... women and men taking these drugs to postpone dental ... exacerbate the problem. Thats when Zavras, an associate professor ...
... misguided zealots are promoting numerous stress reduction devices, ... The vast majority are supported only by ... others. Very often, as in the case ... stress, scholarly articles from prestigious journals are cited ...
Cached Medicine News:Health News:Obesity linked to decreased seatbelt use 2Health News:MRI techniques evolving towards better assessment of liver fibrosis 2Health News:Mayo Clinic Proceedings provides forum for debate about capital punishment 2Health News:Mayo Clinic Proceedings provides forum for debate about capital punishment 3Health News:Smoking rate among New York City teens was lowest on record in 2007 2Health News:Smoking rate among New York City teens was lowest on record in 2007 3Health News:Oral osteoporosis meds appear to reduce the risk of jaw degradation 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: